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Background: As variation in care has previously been linked to quality, we aimed to describe variations in inflammatory bowel diseases care by
gastroenterology (GI) practice setting.
Methods: We performed a cross-sectional study within the Crohn’s and Colitis Foundation of America Partners and used bivariate analyses to compare
patient characteristics by GI practice setting (GI-academic [GIA], GI-private, or GI-other). Regression models were used to describe the effects of
provider type on steroid use, disease activity, and the quality of life.
Results: The study included 12,083 patients with inflammatory bowel diseases (7576 with Crohn’s disease [CD] and 4507 with ulcerative colitis [UC]).
Nearly 95% reported visiting a GI provider annually. Also, CD patients seen by GIA were younger, better educated, used less 5-aminosalicylate agents,
and had higher biologic and immunomodulator use (P , 0.001 for all). On multivariate analysis of CD patients, GIA used less steroids when compared
with GI-private (odds ratio, 0.84; 95% confidence interval, 0.67–1.06) or GI-other (odds ratio, 0.66; 95% confidence interval, 0.49–0.89). GIA patients
were more likely to be in remission, have flu vaccine, and have better quality of life. UC patients seen by GIA were younger, had more hospitalizations,
and previous surgery (P , 0.001 for all). No differences existed for steroid use, remission, flu vaccine, or quality of life for UC care on bivariate or
multivariate analyses.
Conclusions: Significant variations in care patterns and quality measures exist for CD across GI provider types, without similar variation in UC care.
Interventions to reduce variations in care could improve the quality of care in CD.
(Inflamm Bowel Dis 2016;22:2672–2677)
T he art of medicine allows for some expected variation inpractice; however, extreme variations in care have been used
as markers of poor quality of care whether secondary to insuffi-
cient evidence, lack of knowledge, misuse of health care resources,
or multiple equally effective approaches.1,2 Such variation is evi-
dent in the care of both ulcerative colitis (UC) and Crohn’s dis-
ease (CD) patients, although more prominent in the latter due to
its heterogeneous nature.
Spiegel et al2 showed that a wide variation in the everyday
management of UC exists between community and expert gas-
troenterologists when presented with clinical vignettes. Simi-
larly, significant variations in CD management were seen
between community and expert gastroenterologists when pro-
vided with sample case vignettes,3 especially with regards to
the use of 5-aminosalicylate (5-ASA) medications. However,
the response of a physician to a vignette may differ greatly from
their management of actual patients.
Due to the variation in care evidenced in individuals with
inflammatory bowel diseases (IBD), the American Gastroentero-
logical Association developed an IBD performance measurement
set with the intent of improving health outcomes through
increased patient safety with an emphasis on preventive care
and noncorticosteroid-based treatment options.4 The Crohn’s and
Colitis Foundation of America (CCFA) also sponsored the pub-
lication of a set of quality indicators (QIs) in IBD management,
including treatment, surveillance, and preventive care.1 Use of
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such QIs establishes measurable benchmarks that can assess base-
line quality of care and provide measurable standards for subse-
quent improvement in care.5,6
A focus on quality improvement and the development of
evidence-based treatment guidelines has led to improved out-
comes including decreased morbidity and mortality in other
chronic diseases, such as cystic fibrosis.7 Prior studies that have
examined the differences in practice patterns of IBD care com-
paring community and expert gastroenterologists have been small
in size and based on clinical vignettes. In our study, we aimed to
use CCFA Partners to describe variations in medication use,
remission rates, and quality of life measurements in individuals
with UC and CD by gastroenterology (GI) practice setting.
METHODS
Crohn’s and Colitis Foundation of
America Partners
We used an Internet-based cohort, CCFA Partners, to
describe variations in medication use, remission rates, and quality
of life measurements by GI practice setting for individuals with
self-reported IBD. CCFA Partners follows individuals with IBD
who were recruited from CCFA e-mail lists and other social
media outlets. Participants complete baseline and semiannual
follow-up surveys regarding demographic, disease location and
activity, medication use, prevention activities including vaccina-
tion and screenings, and quality of life measurements. Baseline
characteristics of the population and further details of the cohort
have been described elsewhere.8
Data Collection and Management
Data were collected in a Web-based format, and the
interface performed range and consistency checks to improve
data quality. The data management system has been previously
described.8 Special software was not required, and the Web forms
were accessible from any computer running a modern Internet
browser with an active Internet connection. Data on demograph-
ics, GI practice setting, disease type, IBD medications, remission,
vaccination status, and quality of life were extracted from CCFA
Partners core data. GI practice settings included GI-academic
(GIA), GI-private (GIP), or GI-other (GIO; managed care or vet-
eran’s administration).
Study Design
We performed a cross-sectional study within CCFA
Partners’ Internet-based cohort including all individuals who
completed a baseline survey, preventive health survey, and quality
of life survey. We collected demographic data including age,
gender, and education level. Factors associated with disease
course, such as prior bowel surgery, hospitalization, and medica-
tion use, were also recorded. We assessed disease activity through
validated self-report instruments including the short Crohn’s dis-
ease activity index9 for CD and the simple clinical colitis activity
index10 for UC. We used previously validated cutoffs for remis-
sion of ,150 for short Crohn’s disease activity index9 and #2 for
simple clinical colitis activity index.11 We obtained data on qual-
ity of life through the short IBD questionnaire (SIBDQ).12 We
questioned participants about influenza vaccination, a QI
endorsed by the American Gastroenterological Association.13
We also collected data on smoking status, which is known to
be associated with the course of both CD and UC.14 Screening
for smoking and recommendation for cessation intervention is
a physician quality reporting system measure for IBD.
Statistical Analysis
Bivariate analyses were used to compare demographics,
disease activity, and SIBDQ by GI practice setting. We used
logistic and linear regression models controlling for factors
associated with complicated disease course, including history of
surgery, hospitalization, smoking, and disease duration, to deter-
mine the independent effects of provider type on outcomes such as
steroid use, disease activity, and quality of life. We accounted for
potential clustering using a robust variance estimator in the models.
STATA 14.0 (College Station, TX) was used for all analyses. P
values less than 0.05 were considered statistically significant. The
Institutional Review Board at the University of North Carolina at
Chapel Hill approved the study protocol.
RESULTS
Study Population
The study included 12,083 individuals with IBD who
completed baseline demographic and preventive health surveys
within CCFA Partners. Of those, 7576 reported having CD and
4507 reported having UC. Seventy-two percent of the study
participants were women. The mean age of the study population
was 42 years, and the mean time from diagnosis to study
participation was 10 years. Nearly 95% reported visiting a GI
provider at least annually. Of those consulting a GI provider,
73.8% saw GIP, 15.1% saw GIA, and 11.1% saw GIO. Additional
demographic information is provided in Table 1.
Characteristics and Outcomes of CD Patients
by Provider Type
CD patients seen by GIA were younger (P , 0.001), better
educated (P , 0.001), used less 5-ASA agents (P , 0.001), and
had higher use of anti–tumor necrosis factor (TNF) agents (P ,
0.001), immunomodulators (P , 0.001), and combination therapy
with immunomodulator and anti-TNF (P, 0.001) (Table 2). Those
seen by GIA also had higher remission rates and flu vaccine rates
with fewer current smokers. Although not statistically significant,
GIA used narcotics in patients with CD at a lower rate (Table 2).
On multivariate analysis controlling for factors associated
with a complicated disease course including surgery, hospital-
izations, smoking status, and disease duration, GIA were less
likely to use steroids for CD patients when compared with GIP
surgery (P, 0.001). UC patients treated at academic sites did use
less 5-ASA (P , 0.001), more anti-TNF agents (P ¼ 0.003),
immunomodulators (P ¼ 0.001), and combination therapy with
anti-TNF and immunomodulator (P ¼ 0.001). However, there
were no differences in the use of steroids, remission rates, flu
vaccine, or SIBDQ for UC care on bivariate (Table 4) or multi-
variate (Table 3) analyses.
DISCUSSION
An inverse relationship exists between variation in care
and quality of care delivered to an individual.3 In recent years,
health care improvement efforts have focused on reducing unin-
tended variation in care in an effort to improve patient outcomes
and decrease costs and resource utilization. This is one of the
first studies to describe variation in adult IBD care by GI practice
setting. We found that significant variations in care patterns and
quality measures exist for CD across GI provider types, without
similar variation in UC care. We recognize that severity of dis-
ease is likely associated with important outcomes, such as ste-
roid use or clinical remission; thus, we did control for factors
associated with a prior complicated disease course. In our study,
patients seen by GIA had increased risk of prior surgery, which
may represent a more severe IBD phenotype. Despite this,
a greater percentage of these complicated CD patients treated
by GIA were in remission on biologic and immunomodulator
therapy with less dependence on corticosteroids. GIA had a high-
er rate of influenza vaccination and also had fewer individuals
who were current smokers within the CD population. It is pos-
sible that this provider group may place a greater emphasis on
health care maintenance and preventive care. Important preven-
tive health maintenance counseling in individuals with IBD in-
cludes yearly discussions about the importance of tobacco
cessation and education about appropriate vaccinations for those
with IBD. For example, yearly influenza vaccine is recommen-
ded in all patients with IBD, with avoidance of live virus vac-
cines in those on immunosuppression.1
Interestingly, there was less variation in care between GI
practice settings within the UC population. There were minor
differences in mediation utilization among UC provider types;
however, overall rates of anti-TNF and immunomodulator use
were much lower for each provider group in UC when compared
with CD. Rates of steroid use and important outcomes, such as
clinical remission and quality of life and preventive health
measures (flu vaccine), did not differ among provider types for
UC patients. Ananthakrishnan et al15 recently described similar
findings in a study population of IBD patients treated at 7 aca-
demic centers. The heterogeneous nature of CD as compared
with UC may account for some of these variations in manage-
ment. Management recommendations for CD patients differ sub-
stantially based on CD phenotype and location and other known
risk factors for severe disease, such as young age at onset and
smoking status. There is also more consensus in UC manage-
ment, including greater expert agreement on a step-up medical
TABLE 1. Characteristics of the Population of Patients








Primary care physician (%
yes)
90.2 90.2 90.1
GI provider (% yes) 94.6 95.2 93.7
GI provider type (of those
with
provider) (%)
Academic 15.1 15.7 13.9
Private 73.8 73.2 74.8
Othera 11.1 11.1 11.3
Age, median (IQR), yr 42 (30–54) 42 (30–54) 42 (31–54)
Gender (% female) 72.1 73.0 70.7
Race (% white) 92.9 93.7 91.6
Education (%. high school) 91.0 90.2 92.4
Disease duration (IQR), yr 10 (4–21) 12 (5–23) 8 (3–17)
Prior hospitalization (% yes) 65.0 74.8 48.4
Prior surgery (% yes) 38.2 51.4 16.0
Medications (% current use)
5-ASA 44.8 34.5 62.0
Biologic anti-TNF 32.1 40.4 18.2
Immunomodulator 25.6 28.5 20.8
Oral steroid 11.1 10.0 13.0
Narcotics 10.9 13.2 6.9
Remission (sCDAI ,150 for
CD and
SCCAI #2 for UC; %
yes)
58.3 42.4
SIBDQ, mean (SD) 4.8 (1.2) 4.7 (1.2) 4.8 (1.2)
Flu vaccine (% yes) 64.9 65.3 64.2
Current smoking (% yes) 7.7 10.1 3.8
aOther includes veteran’s affairs, managed care, and other provider types.
IQR, interquartile range; SCCAI, simple clinical colitis activity index; sCDAI, short
Crohn’s disease activity index; SIBDQ, short inflammatory bowel diseases questionnaire.
(odds ratio [OR], 0.84; 95% confidence interval [CI], 0.67–1.06) 
or GIO (OR, 0.66; 95% CI, 0.49–0.89). The patients seen by GIA 
were also more likely to be in remission (OR, 1.18; 95% CI, 1.02–
1.37 for GIA versus GIP and OR, 1.37; 95% CI, 1.11–1.68 
respectively for GIA versus GIO), more likely to have flu vaccine 
(OR, 1.33; 95% CI, 1.15–1.53 for GIA versus GIP and OR, 1.53; 
95% CI, 1.26–1.87 for GIA versus GIO), and more likely to have 
higher SIBDQ scores (beta coefficient, 0.17 and 0.25 respectively; 
P , 0.001 for both). Additional data are present in Table 3.
Characteristics and Outcomes of UC Patients 
by Provider Type
UC patients who were seen by GIA were younger (P , 
0.001), had more prior hospitalizations (P , 0.001), and prior
approach, the efficacy of medications such as 5-ASA, and the
opportunity for a potentially curative surgery in the setting of
severe disease.
The literature has previously shown differences in the care
received in academic referral practices versus private practices.
Reddy et al16 recently examined care that IBD patients received
before referral to a tertiary center and showed various deficits in
care including underdosing of medications, prolonged use of
corticosteroids, and failure to perform routine health care
maintenance.17 Similar improved outcomes at academic medical
centers are seen in the literature of various other medical sub-
specialties. For example, Veenstra et al18 described the delivery
of higher valued care at academic centers leading to longer over-
all survival for those with stage IV colon cancer. In the cardiac
literature, Patel et al19 detailed greater adherence to established
acute coronary syndrome guidelines in academic hospitals com-
pared with nonacademic hospitals. A recent study also describes
greater use of evidence-based acute and discharge therapies and
TABLE 2. Characteristics of Patients with CD Who Reported a GI Provider; by Type of Provider in CCFA Partners
Characteristic Academic (n ¼ 1120) Private (n ¼ 5215) Othera (n ¼ 788) Pb
Primary care physician (% yes) 88.7 91.6 90.7 ,0.001
Age, median (IQR), yr 37 (27–50) 44 (32–55) 37 (26–51) ,0.001
Gender (% female) 72.6 73.2 73.6 0.87
Race (% white) 94.5 94.3 90.5 0.005
Education (% greater than high school) 93.9 90.3 87.1 ,0.001
Disease duration (IQR), yr 11 (5–20) 12 (5–24) 11 (4–20) ,0.001
Prior hospitalization (% yes) 78.0 73.9 74.8 0.02
Prior surgery (% yes) 56.3 50.6 51.0 0.002
Medications (% current use)
5-ASA 24.9 38.6 28.8 ,0.001
Biologic anti-TNF 49.7 40.2 44.4 ,0.001
IM 36.4 28.0 31.4 ,0.001
Combination therapy (anti-TNF + IM) 17.6 11.1 13.6 ,0.001
Oral steroid 8.7 10.2 12.4 0.03
Narcotics 12.1 13.1 15.4 0.11
Remission (sCDAI ,150, % yes) 62.8 58.6 55.2 0.007
SIBDQ, mean (SD) 4.9 (1.2) 4.7 (1.2) 4.6 (1.2) 0.08
Flu vaccine (% yes) 71.6 65.4 62.3 ,0.001
Current smoking (% yes) 6.6 10.5 9.7 ,0.001
aOther includes veteran’s affairs, managed care, and other provider types.
bOverall P by 1-way analysis of variance, Kruskal–Wallis, Pearson’s chi-square as appropriate.
IQR, interquartile range; sCDAI, short Crohn’s disease activity index; SIBDQ, short inflammatory bowel diseases questionnaire; IM, immunomodulator.
TABLE 3. Comparisons of Adjusteda Outcomes by GI Provider Setting Among Patients with CD and UC
Steroid use Remission Flu Vaccine SIBDQb
Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI) Beta Coefficient (95% CI), P
CD
Academic versus private 0.84 (0.67–1.06) 1.18 (1.02–1.37) 1.33 (1.15–1.53) 0.17 (0.09 to 0.25); P , 0.001
Academic versus other 0.66 (0.49–0.89) 1.37 (1.11–1.68) 1.53 (1.26–1.87) 0.25 (0.14 to 0.36); P , 0.001
UC
Academic versus private 1.07 (0.82–1.38) 1.02 (0.83–1.26) 1.14 (0.94–1.38) 20.01 (20.12 to 0.10); P ¼ 0.83
Academic versus other 0.96 (0.68–1.37) 1.11 (0.84–1.47) 1.07 (0.82–1.39) 20.03 (20.19 to 0.12); P ¼ 0.68
aAdjusted for surgery, hospitalization, smoking status, and disease duration.
bShort inflammatory bowel disease questionnaire.
characteristics or preferences or both. Because CCFA Partners
data are self-reported, there is also a potential for misclassification
of disease status or type. However, the validity of self-reported
IBD in CCFA Partners has been previously demonstrated.21 Addi-
tionally, there may be an element of recall bias especially with
regards to the rate of influenza vaccination. Prior studies have
demonstrated that self-report likely overestimates true vaccination
status.22 We would argue that any misclassification in the case of
vaccination is likely nondifferential because we do not expect an
individual to fail to report receiving an influenza vaccination
based on their provider type. Identification of provider type was
also by patient report. Although misclassification is possible, this
is also most likely to be nondifferential. Because this was a cross-
sectional study design of baseline data, we do not have access to
disease activity instruments preceding the outcome measures.
However, we did control for disease duration, prior surgery, and
prior hospitalization, all prior markers of a more complicated
disease course.
As we continue to witness the expansion in treatment
options available for both CD and UC, we must take action to
reduce unintended variation in care. There has been great success
in decreasing variation, improving care delivery, and thus out-
comes in chronic diseases such as cystic fibrosis and pediatric
IBD.7,23,24 In both scenarios, quality improvement efforts aimed at
better using previously available therapies and the function of the
TABLE 4. Characteristics of Patients With UC Who Reported a GI Provider; by Type of Provider in CCFA Partners
Characteristic Academic (n ¼ 582) Private (n ¼ 3125) Other (n ¼ 472)a Pb
Primary care physician (% yes) 88.8 90.6 93.2 0.01
Age, median (IQR), yr 37 (28–51) 43 (32–55) 36 (27–51) ,0.001
Gender (% female) 73.2 70.9 68.4 0.24
Race (% white) 91.2 92.1 89.5 ,0.001
Education (% greater than high school) 93.8 93.0 89.6 0.02
Disease duration (IQR), yr 8 (3–14) 8 (3–17) 6 (3–14) ,0.001
Prior hospitalization 59.3 45.1 53.2 ,0.001
Prior surgery (% yes) 21.8 12.9 16.5 ,0.001
Medications (% current use)
5-ASA 57.7 66.6 62.5 ,0.001
Biologic anti-TNF 24.2 18.2 20.1 0.003
IM 28.0 21.0 21.6 0.001
Combination therapy (anti-TNF + IM) 8.9 5.3 4.2 0.001
Oral steroid 14.5 13.3 15.0 0.50
Narcotics 7.4 7.0 4.5 0.12
Remission (SCCAI #2), (% yes) 42.9 43.4 40.5 0.55
SIBDQ, mean (SD) 4.8 (1.3) 4.9 (1.2) 4.8 (1.2) 0.19
Flu vaccine (% yes) 66.7 63.6 65.3 0.32
Current smoking (% yes) 2.8 3.6 3.0 0.51
aOther includes veteran’s affairs, managed care, and other provider types.
bOverall P by 1-way analysis of variance, Kruskal–Wallis, Pearson’s chi-square as appropriate.
IQR, interquartile range; SCCAI, simple clinical colitis activity index; SIBDQ, short inflammatory bowel diseases questionnaire; IM, immunomodulator.
improved 30-day outcomes for those individuals presenting to 
an academic medical center with a non–ST-elevation myocardial 
infarction compared with a nonacademic medical center.20
There are numerous strengths to our study on variation in 
care in patients with IBD by GI practice setting. CCFA Partners 
includes a large and geographically diverse population. There is 
also diversity in provider type, whereas other studies have 
focused largely on academic centers. In addition, we measured 
actual care delivery and outcomes directly through patient 
report, an advantage over prior studies that used clinical 
vignettes to assess theoretical care patterns. We include impor-
tant patient-reported outcomes such as SIBDQ that have not 
previously been measured in studies of variation in care in IBD. 
Prior studies have largely focused on treatment variations rather 
than on patient-reported outcomes.
We do acknowledge several limitations to our study. CCFA 
Partners is a volunteer sample of patients, thus may not be 
representative of general U.S. IBD population. Individuals with 
lower socioeconomic status, education level, and minority ethnic 
status may be underrepresented in this population due to the lack 
of Internet access and insufficient literacy to complete the online 
questionnaires. Unfortunately, this is a known limitation of 
Internet-based research.21 It is also difficult to ascertain if varia-
tion in care between GIA and GIP is due to differences in provider 
or care center practices or due to differences in patient
health care delivery system resulted in significant outcome im-
provements for these individuals, with reduced variation in care.
Although this is certainly promising, it may be more difficult to
implement similar efforts in the adult population. For example,
much of pediatric IBD care is centered at large academic centers
compared with community practices, whereas adult IBD care is
focused in the community.
CCFA is dedicated to quality improvement through the
development of care pathway algorithms, QIs, and a more
systematic and multidisciplinary approach to IBD care to ensure
that all individuals with IBD are receiving optimal care regardless
of GI provider type.25 Our data show the existence of significant
gaps in IBD care. Initial quality improvement efforts aimed at
disseminating the available evidenced-based guidelines may
result in improved patient care, a healthier IBD population,
reduced health care costs, and less disconnect between the differ-
ent GI provider types.3,13 Collaboration between different pro-
vider types and redesigning elements of the chronic care
delivery system will certainly be necessary to optimize the care
of IBD patients.
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